Publications by authors named "B Melotti"
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.
Lung Cancer
December 2024
Background: The upfront treatment of non-oncogene-addicted NSCLC relies on immunotherapy alone (ICI) or in combination with chemotherapy (CT-ICI). Genomic aberrations such as KRAS, TP53, KEAP1, SMARCA4, or STK11 may impact survival outcomes.
Methods: We performed an observational study of 145 patients treated with first-line IO or CT-ICI for advanced non-squamous (nsq) NSCLC at our institution tested with an extensive lab-developed NGS panel.
: Dabrafenib and trametinib (D + T) have been approved for the treatment of stage III melanoma with BRAF V600E V600K mutations in an adjuvant setting, based on the results from the COMBI-AD trial. To provide early access to this combination therapy prior to its commercial availability in Italy, a Managed Access Program (MAP) was run in Italy from June 2018 to December 2019. : The MADAM (Maximing ADjuvAnt MAP) study is an Italian retrospective-prospective observational study that included patients who received at least one dose of D + T through the MAP.
View Article and Find Full Text PDFArticle Synopsis
- - Melanoma cases are on the rise, leading to frequent updates in guidelines for diagnosis, staging, and treatment; recent approvals now include adjuvant therapy for stage IIb/c melanoma.
- - A study involving 92 melanoma patients revealed that those with stage IIb/c have a later age of diagnosis and a higher occurrence of specific characteristics like ulceration and angiotropism compared to stage IIIa patients.
- - While not statistically significant, stage IIb/c patients showed a higher rate of metastasis over a 5-year period (15%) compared to those with stage IIIa melanoma (4%), highlighting the potential benefits of adjuvant immunotherapy for stage IIb/c patients.
Article Synopsis
- Approximately 10% of lung adenocarcinomas (LUAD) have mucinous histology (LUADMuc), which is linked to a lighter/absent smoking history and a higher prevalence of KRAS mutations compared to LUAD without this histology (LUADnon-muc).
- A study analyzed features and treatment outcomes of LUADMuc and LUADnon-muc patients, revealing LUADMuc patients had less aggressive disease characteristics and a poorer response to current therapies, especially immunotherapy.
- Overall, LUADMuc showed lower objective response rates, shorter progression-free and overall survival compared to LUADnon-muc, highlighting a need for more effective treatment strategies for this subgroup.
Article Synopsis
- * In a study at an institution, two patients with class 3-mutated NSCLC showed significant responses to the EGFR tyrosine kinase inhibitor erlotinib after previous treatments failed; one achieved complete response and the other had a partial response.
- * Research indicated that class 3-mutated NSCLC cell lines demonstrated sensitivity to EGFR-TKIs at lower concentrations compared to class 1 and 2 mutations, suggesting that class 3 mutations could represent a new targetable group for treatment.